Trishula Therapeutics, a spinout from Tizona, is a clinical-stage antibody company focused on immunotherapy. It’s first-in-class anti-CD39 program (TTX-030) is partnered with AbbVie and being studied in Phase 1/1b clinical trials as a monotherapy and in combination with an anti-PD-1 agent and standard chemotherapy in adults with advanced cancers.

LocationSan Francisco, CA
CEOAnil Singhal
Partner Kurt von Emster